Mycoplasma Testing

Mycoplasma contamination events can lead to altered physio-chemical properties of cells, potentially resulting in reduced or altered cellular products and perhaps unsafe biopharmaceuticals. Thus, testing for the presence of mycoplasma contamination in development and manufacturing is a requirement by worldwide regulatory agencies. Guidance for this testing is provided in the United States Pharmacopeia (USP) Chapter <63>, European Pharmacopoeia (EP) Chapter 2.6.7 Mycoplasmas, Japanese Pharmacopoeia, Chinese Pharmacopoeia, and FDA 1993 Points to Consider (PTC).

In October 2012, the U.S., European, and Japanese mycoplasma methods were brought into alignment, enabling the creation of harmonized direct culture and indirect cell culture assays. A single assay of each type will now be able to meet or exceed regulatory requirements. For the Chinese market, Eurofins BioPharma Product Testing also offers the CP test.

Eurofins BioPharma Product Testing network of laboratories offers harmonized mycoplasma assays and detection, which comply with the USP <63> monograph, FDA 1993, PTC, JP, CP and the EP 2.6.7 Guidelines, as well as a fully validated 21 CFR 610.30 method.

Why Choose Eurofins BioPharma Product Testing?

• We provide fully characterized and qualified positive control strains.
• We have a formalized analyst training program, including required proficiency assessments using blind samples.
• We perform mycoplasmastasis testing to qualify each assay for each test article.
• With over 20 years of experience, we offer support for mycoplasma clearance studies, including consultation and study design.
• We utilize an optimized proprietary media.

LabAcess

Envío de Muestras